Journal of Hepatology
Volume 52, Issue 2 , Pages 220-227 , February 2010

Identification and expression analysis of the aldo–ketoreductase1-B10 gene in primary malignant liver tumours

  • Stefan Heringlake

      Affiliations

    • Department of Gastroenterology, Ruhr-University Bochum, Knappschaftskrankenhaus, In der Schornau 23-25, 44892 Bochum, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 299 3402; fax: +49 299 3409.
    • ,
  • Michael Hofdmann

      Affiliations

    • Department of Gastroenterology and Hepatology, Medical University of Hannover, Germany
    • ,
  • Anette Fiebeler

      Affiliations

    • Department of Nephrology, Medical University of Hannover, Germany
    • ,
  • Michael P. Manns

      Affiliations

    • Department of Gastroenterology and Hepatology, Medical University of Hannover, Germany
    • ,
  • Wolff Schmiegel

      Affiliations

    • Department of Gastroenterology, Ruhr-University Bochum, Knappschaftskrankenhaus, In der Schornau 23-25, 44892 Bochum, Germany
    • ,
  • Andrea Tannapfel

      Affiliations

    • Department of Pathology, Ruhr-University Bochum, Germany

Received 17 February 2009 ,Revised 30 August 2009 ,Accepted 15 September 2009.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–156
  2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576
  3. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–125
  4. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology. 2005;128:1655–1667
  5. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008;12:131–150
  6. Yachimski P, Pratt DS. Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol. 2008;42:178–190
  7. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797–1801
  8. Griffiths J, Nix B. Modeling the hepatitis C virus epidemic in France using the temporal pattern of hepatocellular carcinoma deaths. Hepatology. 2002;35:709–715
  9. Sherman M. Alphafetoprotein: an obituary. J Hepatol. 2001;34:603–605
  10. Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570–575
  11. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology. 2002;62:57–63
  12. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 2006;12:1175–1181
  13. Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis. 2006;26:385–390
  14. Maruyama H, Yoshikawa M, Yokosuka O. Current role of ultrasound for the management of hepatocellular carcinoma. World J Gastroenterol. 2008;14:1710–1719
  15. Jin Y, Penning TM. Aldo–keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol. 2007;47:263–292
  16. Takahashi M, Fujii J, Miyoshi E, Hoshi A, Taniguchi N. Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes. Int J Cancer. 1995;62:749–754
  17. Zeindl-Eberhart E, Jungblut PR, Otto A, Rabes HM. Identification of tumor-associated protein variants during rat hepatocarcinogenesis. Aldose reductase. J Biol Chem. 1994;269:14589–14594
  18. Zeindl-Eberhart E, Jungblut PR, Otto A, Kerler R, Rabes HM. Further characterization of a rat hepatoma-derived aldose-reductase-like protein–organ distribution and modulation in vitro. Eur J Biochem. 1997;247:792–800
  19. Saraswat M, Mrudula T, Kumar PU, Suneetha A, Rao Rao TS, Srinivasulu M, et al. Overexpression of aldose reductase in human cancer tissues. Med Sci Monit. 2006;12:CR525–CR529
  20. Jin J, Krishack PA, Cao D. Role of aldo–keto reductases in development of prostate and breast cancer. Front Biosci. 2006;11:2767–2773
  21. Matz M, Shagin D, Bogdanova E, Britanova O, Lukyanov S, Diatchenko L, et al. Amplification of cDNA ends based on template-switching effect and step-out PCR. Nucleic Acids Res. 1999;27:1558–1560
  22. Lisitsyn N, Lisitsyn N, Wigler M. Cloning the differences between two complex genomes. Science. 1993;259:946–951
  23. Hubank M, Schatz DG. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res. 1994;22:5640–5648
  24. Hubank M, Schatz DG. CDNA representational difference analysis: a sensitive and flexible method for identification of differentially expressed genes. Methods Enzymol. 1999;303:325–349
  25. Michiels L, Van Leuven F, van den Oord JJ, De Wolf-Peeters C, Delabie J. Representational difference analysis using minute quantities of DNA. Nucleic Acids Res. 1998;26:3608–3610
  26. O’Neill MJ, Sinclair AH. Isolation of rare transcripts by representational difference analysis. Nucleic Acids Res. 1997;25:2681–2682
  27. Pastorian K, Hawel L, Byus CV. Optimization of cDNA representational difference analysis for the identification of differentially expressed mRNAs. Anal Biochem. 2000;283:89–98
  28. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol. 2000;18:457–459
  29. von Stein OD, Thies WG, Hofmann M. A high throughput screening for rarely transcribed differentially expressed genes. Nucleic Acids Res. 1997;25:2598–2602
  30. Franz O, Bruchhaus II, Roeder T. Verification of differential gene transcription using virtual northern blotting. Nucleic Acids Res. 1999;27:e3
  31. Tannapfel A, Geissler F, Köckerling F, Katalinic A, Hauss J, Wittekind C. Apoptosis and proliferation in relation to histopathological variables and prognosis in hepatocellular carcinoma. J Pathol. 1999;187:439–445
  32. Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J, et al. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst. 1999;91:1154–1158
  33. Tannapfel A, Engeland K, Weinans L, Katalinic A, Hauss J, Mössner J, et al. Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Br J Cancer. 1999;80:1069–1074
  34. Scuric Z, Stain SC, Anderson WF, Hwang JJ. New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology. 1998;27:943–950
  35. Cao D, Fan ST, Chung SS. Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem. 1998;273:11429–11435
  36. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarrays: Identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 2001;61:2129–2137
  37. Fukumoto S, Yamauchi N, Moriguchi H, Hippo Y, Watanabe A, Shibahara J, et al. Overexpression of the aldo–keto reductase family protein AKR1B10 is highly correlated with smokers’ non-small cell lung carcinomas. Clin Cancer Res. 2005;11:1776–1785
  38. Breton J, Gage MC, Hay AW, Keen JN, Wild CP, Donnellan C, et al. Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo–keto reductase 1C2 and 1B10 dysregulation in Barrett’s esophagus and esophageal adenocarcinoma. J Proteome Res. 2008;7:1953–1962
  39. Yoshitake H, Takahashi M, Ishikawa H, Nojima M, Iwanari H, Watanabe A, et al. Aldo–keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int J Gynecol Cancer. 2007;17:1300–1306
  40. Yan R, Zu X, Ma J, Liu Z, Adeyanju M, Cao D. Aldo–keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention. Int J Cancer. 2007;121:2301–2306
  41. Tammali R, Reddy AB, Ramana KV, Petrash JM, Srivastava SK. Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation. Carcinogenesis. 2009;30:799–807
  42. Gallego O, Ruiz FX, Ardèvol A, Domínguez M, Alvarez R, de Lera AR, et al. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci USA. 2007;104:20764–20769[Epub 2007 Dec 17]
  43. Crosas B, Hyndman DJ, Gallego O, Martras S, Parés X, Flynn TG, et al. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem J. 2003;373:973–979
  44. Dragnev KH, Rigas JR, Dmitrovsky E. The retinoids and cancer prevention mechanisms. Oncologist. 2000;5:361–368
  45. Penning TM. AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers. Clin Cancer Res. 2005;11:1687–1690
  46. Ma J, Yan R, Zu X, Cheng JM, Rao K, Liao DF, et al. Aldo–keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem. 2008;283:3418–3423[Epub 2007 Dec 1]
  47. Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, et al. Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics. 2004;3:960–969[Epub 2004 Jul 6]
  48. Nie L, Wu G, Zhang W. Correlation between mRNA and protein abundance in Desulfovibrio vulgaris: a multiple regression to identify sources of variations. Biochem Biophys Res Commun. 2006;339:603–610[Epub 2005 Nov 17]
  49. Brockmann R, Beyer A, Heinisch JJ, Wilhelm T. Posttranscriptional expression regulation: what determines translation rates?. PLoS Comput Biol. 2007;3:e57
  50. Liu Z, Zhong L, Krishack PA, Robbins S, Cao JX, Zhao Y, et al. Structure and promoter characterization of aldo–keto reductase family 1 B10 gene. Gene. 2009;437:39–44[Epub 2009 Feb 21]
  51. Teramoto R, Minagawa H, Honda M, Miyazaki K, Tabuse Y, Kamijo K, et al. Protein expression profile characteristic to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning. Biochim Biophys Acta. 2008;1784:764–772[Epub 2008 Mar 5]
  52. Martin HJ, Breyer-Pfaff U, Wsol V, Venz S, Block S, Maser E. Purification and characterization of AKR1B10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab Dispos. 2006;34:464–470[Epub 2005 Dec 28]

PII: S0168-8278(09)00731-4

doi: 10.1016/j.jhep.2009.11.005

Journal of Hepatology
Volume 52, Issue 2 , Pages 220-227 , February 2010

Article Tools

* Image Usage & Resolution